Treatment Outcomes of Facial Rejuvenation With a Novel Hyaluronic Acid Filler in Asian Women
Abstract
We conducted this study to assess the short-term treatment outcomes and safety of facial rejuvenation with the YVOIRE volume plus (LG Chem Ltd., Seoul) in Asian women. In this multicenter, retrospective study, we evaluated a total of 291 women (n = 291) who received a facial rejuvenation with the YVOIRE volume plus. We monitored time-dependent changes in the mean Global Aesthetic Improvement Scale (GAIS) scores at 3, 6, 9, and 12 months. In addition, we estimated the duration of efficacy based on the Kaplan-Meier survival analysis. Furthermore, we analyzed incidences of postoperative complications. Our clinical series of the patients achieved mean GAIS scores of 3.44 ± 0.69 points. There were no significant time-dependent changes in the mean GAIS scores (P > .05). Moreover, the duration of efficacy was estimated at 242.71 ± 17.85 days (95% confidence interval: 228.59-263.44). A total of 37 cases (12.7%) of postoperative complications occurred, all of them were of mild severity. In conclusion, our surgical technique, combined with YVOIRE volume plus, is of significance in that it attempted to address both dynamic and static aspects of the facial rejuvenation. But this deserves further studies using 3-dimensional imaging modalities.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.